Filing Analysis
Century Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ended June 30, 2026, and provided an updated investor presentation.
📋 Key Facts
- Announced financial results for the quarter ended June 30, 2026 (Item 2.02).
- Released an updated slide presentation for investor meetings (Item 7.01).
- Filed as an emerging growth company.
Century Therapeutics, Inc. announced the resignation of Dr. Carlo Rizzuto from its Board of Directors, effective December 18, 2025. The company stated that the resignation was not due to any disagreement regarding operations, policies, or practices.
🚩 Red Flags
- None identified; the filing explicitly states no disagreement exists between the departing director and the company.
📋 Key Facts
- Dr. Carlo Rizzuto resigned from the Board of Directors on December 18, 2025.
- The resignation was voluntary and not related to any disagreements with the Company's operations, policies, or practices.
- Effective date of departure: December 18, 2025.
Century Therapeutics, Inc. filed an 8-K to provide updated investor presentation materials under Regulation FD. The filing serves to update information used in upcoming meetings with investors.
📋 Key Facts
- The company updated its slide presentation dated December 12, 2025 (Exhibit 99.1).
- The disclosure is being furnished pursuant to Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
- The updated presentation will be used in various investor meetings.
Century Therapeutics, Inc. expanded its Board of Directors from six to eight members by appointing Dr. Martin Murphy and Dr. Han Lee as new independent directors.
📋 Key Facts
- Board size increased from 6 to 8 members effective December 9, 2025.
- Dr. Martin Murphy appointed as Class III director; will serve on Compensation and Nominating/Corporate Governance Committees.
- Dr. Han Lee appointed as Class II director; will serve on Compensation and Audit Committees.
- Both directors received initial option awards for 88,000 shares of common stock vesting over 36 months.
- Each new director receives an annual cash retainer of $40,000.
Century Therapeutics, Inc. issued an 8-K to report its financial results for the quarter ended September 30, 2025, and updated its investor presentation. Additionally, the company announced a new program targeting Type 1 diabetes (CNTY-813).
📋 Key Facts
- Reported quarterly financial results for the period ending September 30, 2025.
- Released an updated investor slide presentation (Exhibit 99.2).
- Announced its first program for Type 1 diabetes, identified as CNTY-813.
Century Therapeutics failed to regain compliance with Nasdaq's $1.00 minimum bid price requirement by the initial deadline of August 26, 2025. Consequently, the company has been granted a 180-day extension until February 23, 2026, and has been transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market.
🚩 Red Flags
- Failure to meet minimum bid price requirement by initial deadline.
- Downgrade in listing tier (Global Select Market to Capital Market).
- Explicit mention of a potential reverse stock split to regain compliance, which often results in shareholder dilution or psychological resistance.
📋 Key Facts
- Initial compliance deadline for the $1.00 Bid Price Rule was August 26, 2025; company failed to meet this requirement.
- Nasdaq granted an extension until February 23, 2026, to regain compliance with the Bid Price Rule.
- The company's listing was transferred from The Nasdaq Global Select Market to The Nasdaq Capital Market effective August 27, 2025.
- Company has explicitly stated it is considering a reverse stock split as a potential method to cure the deficiency.
Century Therapeutics announced significant leadership changes including the appointment of CEO Brent Pfeiffenberger as Chairman and the departure of two Board members. The company also approved a consulting agreement for departing director Joseph Jimenez and a large RSU retention award for the CEO.
🚩 Red Flags
- Reduction in Board size from eight to six members.
- Departure of two directors (Jimenez and Butitta) simultaneously.
- Related-party transaction: Consulting agreement with departing director Joseph Jimenez involving continued vesting of equity awards.
📋 Key Facts
- CEO Brent Pfeiffenberger appointed Chairman of the Board, effective August 14, 2025.
- Joseph Jimenez and Cynthia Butitta are stepping down from the Board, effective August 14, 2025.
- The Board size is being reduced from eight to six members.
- Joseph Jimenez entered into a consulting agreement with the Company starting August 14, 2025.
- CEO Brent Pfeiffenberger was granted 1,587,614 restricted stock units (RSUs) as a retention award, vesting in two tranches (50% on year 2 and 50% on year 3).
- The company released Q2 2025 financial results and an updated investor presentation.
Century Therapeutics is implementing a massive reduction in force (RIF) involving approximately 51% of its headcount to 'right size' the organization. This restructuring includes the departure of both the CFO and CDO, effective July and August 2025, respectively.
🚩 Red Flags
- Massive headcount reduction (51%) suggests significant financial distress or a radical shift in capital allocation.
- Loss of key executive leadership (CFO and CDO) simultaneously during a restructuring phase.
- High cash burn implication: $3.7 million in immediate severance costs for a micro-cap/mid-cap biotech.
📋 Key Facts
- Net reduction in employee headcount by approximately 51%.
- Estimated termination costs of $3.7 million, primarily cash severance.
- Workforce reduction expected to be substantially completed by the end of Q3 2025.
- CFO Morgan Conn, Ph.D. departing effective July 11, 2025 (termination without cause).
- CDO Adrienne Farid, Ph.D. departing effective July 31, 2025 (termination without cause).
- Douglas Carr appointed as interim Principal Financial Officer.
Century Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on June 12, 2025. The meeting resulted in the election of two Class I directors and the ratification of Ernst & Young LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held virtually on June 12, 2025.
- Daphne Quimi was elected to the Board of Directors (Class I) with 52,593,454 votes 'For'.
- Carlo Rizzuto, Ph.D. was elected to the Board of Directors (Class I) with 51,373,990 votes 'For'.
- Ernst & Young LLP was ratified as independent registered public accountant for the 2025 fiscal year with 71,768,193 votes 'For'.
- Record date for the meeting was April 16, 2025, with 86,158,758 shares outstanding.
Century Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ended March 31, 2025 and provided an updated investor presentation.
📋 Key Facts
- Announced financial results for the quarter ended March 31, 2025 via press release (Exhibit 99.1).
- Released an updated slide presentation for investor meetings (Exhibit 99.2).
- The company is classified as an 'emerging growth company'.
Century Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024, and provided an updated investor presentation.
📋 Key Facts
- Company released full-year 2024 financial results on March 19, 2025.
- Updated a slide presentation for use in future investor meetings (Exhibit 99.2).
- The filing is an emerging growth company disclosure.
Century Therapeutics received a deficiency notice from Nasdaq because its common stock closed below the $1.00 minimum bid price for 31 consecutive business days. The company has 180 days to regain compliance or face potential delisting from the Nasdaq Global Select Market.
🚩 Red Flags
- Delisting notice (Rule 5450(a)(1) deficiency)
- Stock price has been below $1.00 for over a month
- Risk of market tier downgrade if compliance is not met
📋 Key Facts
- Received 'Bid Price Letter' from Nasdaq on February 26, 2025.
- Closing bid price has been below $1.00 for the last 31 consecutive business days.
- The company has a 180-day compliance period ending August 25, 2025.
- Compliance requires maintaining a closing bid price of at least $1.00 for at least 10 consecutive business days.
- Failure to cure may result in a transfer from the Nasdaq Global Select Market to the Nasdaq Capital Market.
Century Therapeutics announced its preliminary cash position as of December 31, 2024, and updated its investor presentation. The company reported approximately $220 million in cash, cash equivalents, and investments.
🚩 Red Flags
- Financial data is unaudited and subject to change upon completion of financial closing procedures.
📋 Key Facts
- As of December 31, 2024, the Company had approximately $220 million in cash, cash equivalents, and investments.
- The reported amount is unaudited and preliminary as of January 13, 2025.
- The company updated its investor presentation (Exhibit 99.1) for use in upcoming meetings with investors.
Century Therapeutics announced that Bristol-Myers Squibb (BMS) is terminating its Research, Collaboration and License Agreement without cause. The termination will be effective March 12, 2025.
🚩 Red Flags
- Loss of a major strategic partner (Bristol-Myers Squibb) in the biotech sector.
- Termination follows an 'internal corporate portfolio prioritization process' by BMS, suggesting a shift in their strategic focus away from Century's specific programs.
- The company is undergoing a 'strategic review' of its pre-clinical pipeline.
📋 Key Facts
- BMS notified the Company on December 12, 2024, of the termination of the Collaboration Agreement.
- The agreement was originally entered into on January 7, 2022.
- Termination is 'without cause' and will be effective March 12, 2025.
- The collaboration focused on iPSC-derived engineered natural killer cell and gamma delta T cell programs for hematologic malignancies.
Century Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ended September 30, 2024 and provided an updated investor presentation.
📋 Key Facts
- Reported financial results for the quarter ended September 30, 2024 via press release (Exhibit 99.1).
- Issued an updated slide presentation for investor meetings (Exhibit 99.2).
- The company is classified as an 'emerging growth company'.
Century Therapeutics, Inc. announced the appointment of Morgan Conn, Ph.D., as its new Chief Financial Officer and principal financial officer, effective October 14, 2024.
📋 Key Facts
- Morgan Conn, Ph.D. to join as CFO effective October 14, 2024.
- Annual base salary set at $470,000 with a 40% target annual performance bonus.
- One-time signing bonus of $100,000.
- Equity compensation includes an option for 360,890 shares and RSU award for 60,148 shares.
- Dr. Conn previously served as Chief Business Officer at Pharvaris N.V. and held leadership roles at PTC Therapeutics.
Century Therapeutics, Inc. issued an 8-K to announce its financial results for the quarter ended June 30, 2024, and provided an updated investor presentation.
📋 Key Facts
- Report date: August 8, 2024
- Financial results announced for the quarter ended June 30, 2024 (Item 2.02)
- Updated investor slide presentation provided via Regulation FD disclosure (Item 7.01)
Century Therapeutics, Inc. filed an 8-K to update its investor presentation materials. The company intends to use the updated slides in upcoming meetings with investors.
📋 Key Facts
- The filing was made on July 8, 2024.
- The primary purpose is to provide an updated slide presentation (Exhibit 99.1).
- The company intends to use the updated presentation for investor relations meetings.
Century Therapeutics, Inc. filed an amendment to its April 11, 2024, 8-K to provide required financial statements and pro forma information following its acquisition of Clade Therapeutics, Inc.
🚩 Red Flags
- The filing is an amendment to provide missing required financial information from a previous acquisition announcement.
📋 Key Facts
- The filing is an Amendment (Form 8-K/A) to the original report filed on April 11, 2024.
- Century Therapeutics acquired Clade Therapeutics, Inc. effective April 11, 2024.
- Includes audited financial statements of Clade for the year ended December 31, 2023 (Exhibit 99.1).
- Includes unaudited pro forma condensed combined financial statements as of December 31, 2023 (Exhibit 99.2).
Century Therapeutics, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on June 20, 2024. The meeting included the election of three Class III directors and the ratification of Ernst & Young LLP as independent auditors.
📋 Key Facts
- Held 2024 Annual Meeting of Stockholders on June 20, 2024.
- Elected Kimberly Blackwell, M.D., Joseph Jimenez, and Brent Pfeiffenberger, Pharm.D. to the Board of Directors (Class III) until 2027.
- Ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year 2024.
- Approved an amendment to the Certificate of Incorporation to limit officer liability per Delaware law.
- Record date for meeting was April 24, 2024, with 82,847,375 shares outstanding.
Century Therapeutics issued an 8-K to announce a poster presentation of interim Phase 1 ELiSE-1 study results for CNTY-101 at the ASCO Annual Meeting. The company also updated its investor slide presentation.
📋 Key Facts
- Announced interim results from the ongoing Phase 1 ELiPSE-1 study evaluating CNTY-101 in relapsed or refractory non-Hodgkin lymphoma.
- Presentation occurred at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 - June 4, 2024).
- Updated investor slide presentation provided as Exhibit 99.2.
Century Therapeutics, Inc. issued an 8-K to announce its financial results for the fiscal quarter ended March 31, 2024.
📋 Key Facts
- The filing was made on May 9, 2024.
- Reporting period: Quarter ended March 31, 2024.
- The company is an emerging growth company.
- Financial results were released via a press release (Exhibit 99.1).
Century Therapeutics announced a dual-track capital event: a $60 million private placement of common stock and the acquisition of Clade Therapeutics. The company is simultaneously raising significant cash to fund clinical expansion while executing an M&A transaction.
🚩 Red Flags
- Significant dilution: The issuance of ~15.8M shares at $3.78 represents a major equity event for a micro-cap/small-cap biotech.
- Liquidated damages clause in the Registration Rights Agreement (1% per 30 days) is a punitive term often demanded by aggressive institutional investors.
📋 Key Facts
- Private Placement: Issuance of 15,873,011 shares at $3.78 per share to institutional accredited investors.
- Gross proceeds from private placement expected to be approximately $60 million.
- Acquisition of Clade Therapeutics for an upfront consideration of ~$35 million ($15M cash + 4,535,333 shares).
- Potential clinical development milestone payment of up to $10 million for the Clade acquisition.
- Registration Rights Agreement requires filing a registration statement within 30 days of closing; includes 1% liquidated damages per 30-day period if deadlines are missed.
- BofA Securities acted as sole placement agent.
Century Therapeutics, Inc. filed an 8-K to update its investor presentation materials. The company intends to use the updated slide deck in upcoming meetings with investors.
📋 Key Facts
- The filing was made on April 11, 2024.
- The primary purpose is to provide an updated investor presentation (Exhibit 99.1).
- The company is classified as an 'emerging growth company'.
Century Therapeutics, Inc. issued an 8-K to announce the presentation of preclinical data from its iPSC-derived cell therapy platform at the AACR Annual Meeting 2024.
📋 Key Facts
- The company presented preclinical data regarding its iPSC-derived cell therapy platform on April 8, 2024.
- Data presentation focused on end-to-end capabilities including iPSC reprogramming, differentiation, gene editing, synthetic biology, protein engineering, and computational biology.
- The announcement was made via a press release filed as Exhibit 99.1.
Century Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023, and provided an updated investor presentation.
📋 Key Facts
- Announced full-year 2023 financial results via press release (Exhibit 99.1).
- Updated investor slide presentation for use in upcoming meetings with investors (Exhibit 99.2).
- Filed as an emerging growth company.
Century Therapeutics announced the resignation of its Chief Financial Officer, Michael C. Diem, M.D., effective February 2, 2024. The company has appointed Douglas Carr as interim Principal Financial Officer while searching for a permanent replacement.
🚩 Red Flags
- Unexpected departure of a key C-suite executive (CFO).
📋 Key Facts
- Michael C. Diem, M.D. resigned as CFO on January 15, 2024.
- Resignation becomes effective February 2, 2024.
- Douglas Carr (SVP, Finance and Operations) appointed as interim Principal Financial Officer.
- The company stated the resignation was not due to any disagreement regarding operations, policies, or practices.